Page 19 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine Diagnostics gude of biliary tract cancer

of diagnostic decision-making. Given the absence of Ethics approval and consent to participate
standardized treatment regimens, a combined diagnostic
approach is often necessary. Therefore, further research Not applicable.
and development of a comprehensive review of diagnostic Consent for publication
methods for specific biliary tract diseases should be
pursued in the future. 119 Not applicable.

4. Conclusion Availability of data
Imaging plays a crucial role in the management of CCA. Data are available within the article.
It serves several purposes: First, enabling a confident
diagnosis; second, characterizing and staging the tumor, References
which is essential for planning optimal therapy; and 1. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis
third, predicting treatment response and overall patient of cholangiocarcinoma. BMC Cancer. 2019;19(1):185.
survival. Despite the availability of numerous imaging doi: 10.1186/s12885-019-5391-0
methods, the diagnosis of CCA remains challenging. To 2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis.
date, no single imaging modality has been established as 2008;12(1):131-150, ix.
the most optimal for this tumor. Advancements in modern
imaging technologies, particularly USG, CT, and MRI, doi: 10.1016/j.cld.2007.11.003
aim to improve the accuracy of distinguishing CCA from 3. Sempoux C, Jibara G, Ward SC, et al. Intrahepatic
other biliary diseases. However, further research is needed cholangiocarcinoma: New insights in pathology. Semin Liver
to assess the accuracy of various imaging techniques, Dis. 2011;31:49-60.
especially emerging intraductal methods. An interesting doi: 10.1055/s-0031-1272839
avenue for development would be to leverage the strengths
of the imaging methods described above and create a 4. Yazici C, Niemeyer DJ, Iannitti DA, Russo MW.
diagnostic algorithm that maximizes imaging accuracy. Hepatocellular carcinoma and cholangiocarcinoma: An
update. Expert Rev Gastroenterol Hepatol. 2014;8(1):63-82.
Moreover, the integration of these methods could not only
enhance the precision of CCA detection but also aid in doi: 10.1586/17474124.2014.852468
making more effective therapeutic decisions, ultimately 5. Acalovschi M. Cholangiocarcinoma: Risk factors, diagnosis
improving patient prognosis. and management. Rom J Intern Med. 2004;42(1):41-58.

Acknowledgments 6. Vithayathil M, Khan SA. Current epidemiology of
cholangiocarcinoma in Western countries. J Hepatol.
None. 2022;77(6):1690-1698.

Funding doi: 10.1016/j.jhep.2022.07.022
7. Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin
None. North Am. 2019;99(2):315-335.

Conflict of interest doi: 10.1016/j.suc.2018.12.004
The authors declare no conflicts of interest. 8. Krasinskas AM. Cholangiocarcinoma. Surg Pathol Clin.
2018;11(2):403-429.
Author contributions doi: 10.1016/j.path.2018.02.005
Conceptualization: Zakariya Abdi Yakub, Justyna 9. Kendall T, Verheij J, Gaudio E, et al. Anatomical,
Magdalena Łabądź, David Aebisher, Paweł Woźnicki, histomorphological and molecular classification of
Klaudia Dynarowicz, Angelika Myśliwiec, Dorota cholangiocarcinoma. Liver Int. 2019;39 (Suppl 1):7-18.
Bartusik-Aebisher doi: 10.1111/liv.14093
Writing – original draft: Justyna Magdalena Łabądź, David
Aebisher, Paweł Woźnicki, Klaudia Dynarowicz, 10. Qurashi M, Vithayathil M, Khan SA. Epidemiology of
cholangiocarcinoma. Eur J Surg Oncol. 2023;2023:107064.
Dorota Bartusik-Aebisher
Writing – review & editing: Zakariya Abdi Yakub, Justyna doi: 10.1016/j.ejso.2023.107064
Magdalena Łabądź, David Aebisher, Paweł Woźnicki, 11. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management
Klaudia Dynarowicz, Angelika Myśliwiec, Dorota of cholangiocarcinoma. Gastroenterology. 2013;
Bartusik-Aebisher 145(6):1215-1229.

Volume 3 Issue 1 (2025) 11 doi: 10.36922/arnm.4557